We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are ...

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.4 billion, has been gaining attention in the biotechnology sector for its innovative ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

A combination of two existing chemotherapy drugs has been used to fight bladder cancer successfully for the first time in Singapore. This new union of the two “off-label” drugs – gemcitabine and ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...